

Applicants : Pinsky et al.
U.S. Serial No.: 09/648,389
Filing Date : August 25, 2000
Page 2

material is in brackets and the inserted material is underlined
is attached hereto as Exhibit 1.

B2
--3. (Amended) The method of claim 1, wherein the inhibitor is
a nucleic acid which comprises a polynucleotide
sequence complementary to the polynucleotide
sequence of Early Growth Response Factor - 1
mRNA.--

REMARKS

Claims 1-27 are pending in the subject application. Applicants have hereinabove canceled claims 2, 4, 6 and 8 without prejudice or disclaimer to applicants' rights to pursue the subject matter of these claims in a later-filed application. Further, applicants have amended claim 3. Support for this amendment may be found *inter alia* in the specification as follows: Claim 3: page 11, lines 14-19. Therefore, entry of this amendment is respectfully requested such that claims 1, 3, 5, 7 and 9-27 will be pending.

Detailed action:

The Examiner stated that claims 1-27 are pending in the instant application.

Nucleotide and/or Amino Acid Sequence Disclosure:

The Examiner alleged that this application contains sequences disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R §1.821(a)(1)(2). The Examiner alleged that this application